Serum Biomarkers for Prediction of Response to Methotrexate Monotherapy in Early Rheumatoid Arthritis: Results from the SWEFOT Trial.
Karen HambardzumyanRebecca J BolceJohan Karlsson WallmanRonald F Van VollenhovenSaedis SaevarsdottirPublished in: The Journal of rheumatology (2019)
Low baseline levels of CRP and leptin, and high baseline levels of TNF-RI and VCAM-1 were associated with LDA after 3 months of MTX therapy in patients with eRA. Combination of these 4 biomarkers increased accuracy of prediction. [Trial registration number: NCT00764725].